Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02101736 · ClinicalTrials.gov registry record · Phase 2
Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults
A Phase 2 study of NF1 and Neurofibromatosis, sponsored by University of Alabama at Birmingham.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 12
- Study locations
NCT02101736: Completed Phase 2 study of NF1 and Neurofibromatosis, sponsored by University of Alabama at Birmingham.
NCT02101736 is a Phase 2 study of NF1 and Neurofibromatosis that has completed, run by University of Alabama at Birmingham. The registered enrollment target is 45 participants, below the 73-participant average among 6 other NF1 trials with a reported enrollment target (38% lower). The trial reports 12 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02101736, a Phase 2 study of NF1 and Neurofibromatosis, has completed, sponsored by University of Alabama at Birmingham.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 12
- Study locations
Study Summary
This study, "A Phase II Study of Cabozantinib (XL l84) for Plexiform Neurofibromas in Subjects with Neurofibromatosis Type I in Children and Adults diagnosed with Neurofibromatosis Type 1 (NF1) and have a type of tumor called a plexiform neurofibroma (PN). Neurofibromas are tumors that develop from the cells and tissues that cover the nerves. Plexiform neurofibromas can be disfiguring, painful, and life-threatening. These types of tumors typically do not respond well to most treatment approaches such as chemotherapy, radiation, and surgery because of their slow growth and location near vital structures of the body such as nerves, blood vessels, and the airway. The primary objective is to determine the response rate of NF1 patients with plexiform neurofibromas treated with Cabozantinib therapy using MRI scans. The objective response rate to cabozantinib is defined as ≥ 20% reduction in tumor volume at the end of 12 cycles.
Primary Outcome
We will estimate the objective response rate (ORR) as defined by 20% volumetric MRI response of the target lesion to cabozantinib at 12 months in adolescents and adults with Neurofibromatosis type 1 (NF1) plexiform neurofibromas by volumetric MRI imaging.
Conditions Studied
Interventions
- DRUG Cabozantinib
Study Locations (12)
Illinois
- Lurie Children's Hospital of Chicago - Chicago
- University of Chicago - Chicago
California
- Children's Hospital Los Angeles - Los Angeles
District of Columbia
- Children's National Medical Center - Washington D.C.
Indiana
- Indiana Unversity - Indianapolis
Maryland
- National Cancer Institute (NCI) - Bethesda
Massachusetts
- Children' Hospital Boston and Massachusetts General Hospital - Boston
Missouri
- Washington University - St. Louis - St Louis
New York
- New York University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2014-06 |
| Est. Completion | 2022-02-16 |
| Phase | Phase 2 |
What the finished NCT02101736 record still lists
NCT02101736 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 73-participant average among 6 other NF1 trials with a reported enrollment target (38% lower).
The record links to 3 conditions, with NF1 appearing as the primary indexed condition, and to 1 intervention - of which Cabozantinib is the first listed.
NCT02101736 lists 12 locations in 11 states (Illinois, California, District of Columbia).
Frequently Asked Questions
What is clinical trial NCT02101736 about?
NCT02101736 is a clinical study titled "Cabozantinib for Plexiform Neurofibromas (PN) in Subjects With NF1 in Children and Adults". This study, "A Phase II Study of Cabozantinib (XL l84) for Plexiform Neurofibromas in Subjects with Neurofibromatosis Type I in Children and Adults diagnosed with Neurofibromatosis Type 1 (NF1) and have a type of tumor called a plexiform neurofibroma (PN). Neurofibromas are tumors that develop from ...
What is the current status of trial NCT02101736?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2014-06. Estimated completion is 2022-02-16.
What conditions does trial NCT02101736 study?
This clinical trial studies the following conditions: NF1, Neurofibromatosis, Plexiform Neurofibromas.
What interventions are being tested in trial NCT02101736?
The interventions under investigation include: Cabozantinib (DRUG).
Who is sponsoring clinical trial NCT02101736?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02101736 being conducted?
This trial has 12 study locations across California, District of Columbia, Illinois, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NF1
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Interventions for Reading Disabilities in NF1
ACTIVE NOT RECRUITING · Phase 2
-
Mirdametinib Monotherapy in Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF).
RECRUITING · Phase 1
-
A Study of Avutometinib for People With Solid Tumor Cancers
RECRUITING · Phase 1
-
Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
RECRUITING · Phase 1
-
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
ACTIVE NOT RECRUITING · Phase 1
-
Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00804154 · 45 participants · Phase 1
Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer
- NCT01851694 · 45 participants · NA
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
- NCT02896335 · 45 participants · Phase 2
Palbociclib and Pembrolizumab In Central Nervous System Metastases
- NCT03454035 · 45 participants · Phase 1
Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia